JP2005507648A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005507648A5 JP2005507648A5 JP2003514007A JP2003514007A JP2005507648A5 JP 2005507648 A5 JP2005507648 A5 JP 2005507648A5 JP 2003514007 A JP2003514007 A JP 2003514007A JP 2003514007 A JP2003514007 A JP 2003514007A JP 2005507648 A5 JP2005507648 A5 JP 2005507648A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- compound
- nucleic acid
- ntb
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 229920001184 polypeptide Polymers 0.000 claims 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims 21
- 108020004707 nucleic acids Proteins 0.000 claims 14
- 102000039446 nucleic acids Human genes 0.000 claims 14
- 150000007523 nucleic acids Chemical class 0.000 claims 14
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims 12
- 102100029197 SLAM family member 6 Human genes 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 230000000694 effects Effects 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
- 238000012216 screening Methods 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 210000000822 natural killer cell Anatomy 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000004075 alteration Effects 0.000 claims 1
- 210000000628 antibody-producing cell Anatomy 0.000 claims 1
- 230000006037 cell lysis Effects 0.000 claims 1
- 230000001461 cytolytic effect Effects 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 102000046571 human SLAMF6 Human genes 0.000 claims 1
- 230000036737 immune function Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000002853 nucleic acid probe Substances 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01401946 | 2001-07-19 | ||
| PCT/EP2002/007945 WO2003008449A1 (en) | 2001-07-19 | 2002-07-17 | Ntb-a, a surface molecule involved in natural killer cells activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005507648A JP2005507648A (ja) | 2005-03-24 |
| JP2005507648A5 true JP2005507648A5 (enExample) | 2006-01-05 |
| JP4326944B2 JP4326944B2 (ja) | 2009-09-09 |
Family
ID=8182813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003514007A Expired - Fee Related JP4326944B2 (ja) | 2001-07-19 | 2002-07-17 | ナチュラルキラー細胞活性に関与する表面分子ntb−a |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7138243B2 (enExample) |
| EP (1) | EP1406928B1 (enExample) |
| JP (1) | JP4326944B2 (enExample) |
| AT (1) | ATE464320T1 (enExample) |
| AU (1) | AU2002325333B2 (enExample) |
| CA (1) | CA2454185A1 (enExample) |
| DE (1) | DE60235985D1 (enExample) |
| WO (1) | WO2003008449A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04001986A (es) * | 2001-08-29 | 2004-06-07 | Genentech Inc | Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad. |
| WO2006070286A2 (en) | 2004-12-28 | 2006-07-06 | Innate Pharma S.A. | Monoclonal antibodies against nkg2a |
| NO346945B1 (no) | 2006-06-30 | 2023-03-13 | Novo Nordisk As | Anti-NKG2A-antistoffer og anvendelser derav |
| US7847067B2 (en) * | 2006-08-28 | 2010-12-07 | ARCA Biopharma | Antibodies to NTB-A |
| RU2010133892A (ru) | 2008-01-24 | 2012-02-27 | Ново Нордиск А/С (DK) | Гуманизированные моноклональные антитела против человеческого nkg2a |
| CA2838220C (en) | 2011-06-17 | 2020-07-21 | Novo Nordisk A/S | Use of nkg2a antibodies for treatment of bone loss |
| CA2893977C (en) * | 2012-12-21 | 2024-02-13 | Seattle Genetics, Inc. | Anti-ntb-a antibodies and related compositions and methods |
| US10344073B2 (en) | 2014-01-09 | 2019-07-09 | Hadasit Medical Research Services And Development Ltd. | Cell compositions and methods for cancer therapy |
| AU2016299166B2 (en) | 2015-07-24 | 2022-03-31 | Innate Pharma | Methods for detecting tissue infiltrating NK cells |
| US11110171B2 (en) | 2017-12-21 | 2021-09-07 | New York University | PD-1 related cancer therapy |
| EP3752252A4 (en) | 2018-02-12 | 2021-11-17 | Hadasit Medical Research Services and Development Ltd. | MODULATION OF SLAMF6 SPLICE VARIANTS FOR CANCER TREATMENT |
| JP7616610B2 (ja) * | 2020-06-09 | 2025-01-17 | サムスン ライフ パブリック ウェルフェア ファウンデーション | Nk細胞の活性化及び増幅のために遺伝的に操作された細胞株、及びその用途 |
| CN116179488A (zh) * | 2023-03-09 | 2023-05-30 | 广东唯泰生物科技有限公司 | 外周血自然杀伤细胞的体外扩增方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4337197C1 (de) * | 1993-10-30 | 1994-08-25 | Biotest Pharma Gmbh | Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore |
| WO2002024888A2 (en) * | 2000-09-01 | 2002-03-28 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| EP1252333A4 (en) * | 2000-01-25 | 2005-01-05 | Nuvelo Inc | METHODS AND SUBSTANCES RELATING TO CD84-TYPE POLYPEPTIDES AND POLYNUCLEOTIDES |
| US7029677B2 (en) * | 2000-01-25 | 2006-04-18 | Nuvelo, Inc. | Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells |
| AU2001274888A1 (en) * | 2000-05-19 | 2001-12-03 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| US20030180888A1 (en) * | 2000-11-03 | 2003-09-25 | Millennium Pharmaceuticals, Inc. | CD2000 and CD2001 molecules, and uses thereof |
| EP1223218A1 (en) * | 2000-11-03 | 2002-07-17 | Millennium Pharmaceuticals, Inc. | CD2000 and CD2001 molecules and uses thereof |
| EP1377597A4 (en) * | 2001-03-22 | 2005-02-09 | Bristol Myers Squibb Co | POLYNUCLEOTIDE CODING FOR A NEW MEMBER OF THE IMMUNOGLOBULIN SUPERFAMILY, APEX4, AND ITS VARIATIONS AND SPICE VARIANTS |
-
2002
- 2002-07-17 CA CA002454185A patent/CA2454185A1/en not_active Abandoned
- 2002-07-17 US US10/484,139 patent/US7138243B2/en not_active Expired - Fee Related
- 2002-07-17 WO PCT/EP2002/007945 patent/WO2003008449A1/en not_active Ceased
- 2002-07-17 DE DE60235985T patent/DE60235985D1/de not_active Expired - Lifetime
- 2002-07-17 JP JP2003514007A patent/JP4326944B2/ja not_active Expired - Fee Related
- 2002-07-17 AU AU2002325333A patent/AU2002325333B2/en not_active Ceased
- 2002-07-17 AT AT02758350T patent/ATE464320T1/de not_active IP Right Cessation
- 2002-07-17 EP EP02758350A patent/EP1406928B1/en not_active Expired - Lifetime
-
2006
- 2006-11-16 US US11/600,806 patent/US20070065875A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006515749A5 (enExample) | ||
| JP2003501038A5 (enExample) | ||
| JP2011509073A5 (enExample) | ||
| JP2005504513A5 (enExample) | ||
| JP2005507648A5 (enExample) | ||
| JP2004512824A5 (enExample) | ||
| JP2007297407A5 (enExample) | ||
| JP2012115275A5 (enExample) | ||
| CA2316280A1 (en) | Novel g protein-coupled receptor | |
| JP2017514481A5 (enExample) | ||
| JP2009529917A5 (enExample) | ||
| JP2004512006A5 (enExample) | ||
| WO2010065407A2 (en) | High affinity recombinant sea lamprey antibodies selected by a yeast surface display platform | |
| JP2005523681A5 (enExample) | ||
| CA2443345A1 (en) | Disease-associated protein | |
| JP2007526759A5 (enExample) | ||
| JP2008502355A5 (enExample) | ||
| EP4667484A1 (en) | Homodimeric protein combining human il-1r1 with human il-1racp polypeptide fragments and use | |
| JP2005511023A5 (enExample) | ||
| JPH1066585A5 (enExample) | ||
| JP2007508020A5 (enExample) | ||
| JP2006502738A5 (enExample) | ||
| JP2017525368A5 (enExample) | ||
| JP2005516604A5 (enExample) | ||
| JP2005528894A5 (enExample) |